Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. Supplementary table
Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TILs) has demonstrated clinical benefits in metastatic melanoma treatment. However, the clinical application of TILs produced by a widely
This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with che
Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy
Neoadjuvant immunotherapy provides a unique opportunity for understanding therapeutic responses. In this study, the authors analyzed pathologic responses in surgical specimens obtained from 31 squamou
Objective To evaluate the clinical value of immunotherapy in patients with limited-stage small-cell lung cancer (LS-SCLC) receiving prophylactic cranial irradiation (PCI), and to analyze risk factors